Bank of America’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $222K | Sell |
28,751
-5,337
| -16% | -$38.9K | ﹤0.01% | 5313 |
|
|
2025
Q4 | $209K | Sell |
34,088
-585,967
| -95% | -$6.33M | ﹤0.01% | 5325 |
|
|
2025
Q3 | $11.4M | Buy |
620,055
+327,626
| +112% | +$5.26M | ﹤0.01% | 3173 |
|
|
2025
Q2 | $3.8M | Buy |
292,429
+2,098
| +0.7% | +$24.8K | ﹤0.01% | 4167 |
|
|
2025
Q1 | $3.07M | Buy |
290,331
+262,619
| +948% | +$4.17M | ﹤0.01% | 4290 |
|
|
2024
Q4 | $470K | Sell |
27,712
-130,775
| -83% | -$2.46M | ﹤0.01% | 5585 |
|
|
2024
Q3 | $3.68M | Buy |
158,487
+28,426
| +22% | +$608K | ﹤0.01% | 4013 |
|
|
2024
Q2 | $3.17M | Sell |
130,061
-68,496
| -34% | -$2.08M | ﹤0.01% | 4040 |
|
|
2024
Q1 | $6.71M | Buy |
198,557
+158,494
| +396% | +$5.62M | ﹤0.01% | 3362 |
|
|
2023
Q4 | $1.26M | Sell |
40,063
-53,648
| -57% | -$1.28M | ﹤0.01% | 4811 |
|
|
2023
Q3 | $2.39M | Sell |
93,711
-142,403
| -60% | -$4.39M | ﹤0.01% | 4076 |
|
|
2023
Q2 | $6.77M | Sell |
236,114
-762,389
| -76% | -$20.8M | ﹤0.01% | 3090 |
|
|
2023
Q1 | $23.9M | Buy |
998,503
+312,549
| +46% | +$5.61M | ﹤0.01% | 1966 |
|
|
2022
Q4 | $11.6M | Buy |
685,954
+577,968
| +535% | +$10.1M | ﹤0.01% | 2536 |
|
|
2022
Q3 | $1.6M | Buy |
107,986
+89,623
| +488% | +$1.5M | ﹤0.01% | 4480 |
|
|
2022
Q2 | $289K | Sell |
18,363
-38,609
| -68% | -$758K | ﹤0.01% | 5835 |
|
|
2022
Q1 | $1.54M | Sell |
56,972
-70,653
| -55% | -$1.8M | ﹤0.01% | 4839 |
|
|
2021
Q4 | $4.72M | Buy |
127,625
+110,195
| +632% | +$4.49M | ﹤0.01% | 3706 |
|
|
2021
Q3 | $833K | Buy |
17,430
+1,956
| +13% | +$87.6K | ﹤0.01% | 5232 |
|
|
2021
Q2 | $524K | Buy |
15,474
+3,248
| +27% | +$110K | ﹤0.01% | 5387 |
|
|
2021
Q1 | $504K | Buy |
12,226
+5,311
| +77% | +$317K | ﹤0.01% | 5357 |
|
|
2020
Q4 | $300K | Sell |
6,915
-5,905
| -46% | -$400K | ﹤0.01% | 5341 |
|
|
2020
Q3 | $549K | Buy |
12,820
+3,003
| +31% | +$149K | ﹤0.01% | 4643 |
|
|
2020
Q2 | $458K | Sell |
9,817
-5,153
| -34% | -$178K | ﹤0.01% | 4686 |
|
|
2020
Q1 | $203K | Buy |
+14,970
| New | +$192K | ﹤0.01% | 5070 |
|
|
2019
Q1 | – | Sell |
-1,448
| Closed | -$7K | – | 7083 |
|
|
2018
Q4 | $7K | Buy |
+1,448
| New | +$8.9K | ﹤0.01% | 6693 |
|
|
2017
Q4 | – | Sell |
-57
| Closed | -$513 | – | 7012 |
|
|
2017
Q3 | $0 | Sell |
57
-29
| -34% | -$219 | ﹤0.01% | 7039 |
|
|
2017
Q2 | $1K | Buy |
86
+29
| +51% | +$233 | ﹤0.01% | 6795 |
|
|
2017
Q1 | $0 | Sell |
57
-201
| -78% | -$1.86K | ﹤0.01% | 6951 |
|
|
2016
Q4 | $4K | Buy |
258
+188
| +269% | +$2.81K | ﹤0.01% | 6736 |
|
|
2016
Q3 | $1K | Sell |
70
-374
| -84% | -$12.1K | ﹤0.01% | 6908 |
|
|
2016
Q2 | $14K | Buy |
444
+387
| +679% | +$12.2K | ﹤0.01% | 6379 |
|
|
2016
Q1 | $2K | Sell |
57
-652
| -92% | -$22.1K | ﹤0.01% | 6762 |
|
|
2015
Q4 | $31K | Buy |
709
+652
| +1,144% | +$29.4K | ﹤0.01% | 6253 |
|
|
2015
Q3 | $2K | Hold |
57
| – | – | ﹤0.01% | 6951 |
|
|
2015
Q2 | $3K | Hold |
57
| – | – | ﹤0.01% | 6950 |
|
|
2015
Q1 | $2K | Hold |
57
| – | – | ﹤0.01% | 6683 |
|
|
2014
Q4 | $1K | Buy |
+57
| New | +$1.81K | ﹤0.01% | 7547 |
|
|
2014
Q3 | – | Sell |
-486
| Closed | -$59K | – | 7984 |
|
|
2014
Q2 | $59K | Buy |
486
+357
| +277% | +$43.1K | ﹤0.01% | 6528 |
|
|
2014
Q1 | $16K | Buy |
+129
| New | +$19.1K | ﹤0.01% | 7006 |
|
Other funds holding ARCT
AIM
NAMA
VCM
VPM
Bank of America's ARCT Position: Q1 2026 in Review
Bank of America reduced its Arcturus Therapeutics (ARCT) stake by 16% in Q1 2026, selling an estimated $38.9K and leaving 28,751 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #5313.
Bank of America first reported a position in ARCT in Q1 2014 and has held it in 40 quarters since. The position peaked at $23.9M in Q1 2023. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.
- Bank of America held 28,751 shares of Arcturus Therapeutics worth $222K as of Q1 2026.
- Bank of America sold 5,337 Arcturus Therapeutics shares in Q1 2026, an estimated $38.9K.
- Arcturus Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5313 holding.
- Bank of America first reported a position in Arcturus Therapeutics in Q1 2014 and has held it in 40 quarters since.
- Bank of America's Arcturus Therapeutics position peaked at $23.9M in Q1 2023.
- 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.